FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4375846612> ?p ?o ?g. }

• W4375846612 endingPage "929" @default.
• W4375846612 startingPage "918" @default.
• W4375846612 abstract "Abstract Objective This study investigated early, real‐world outcomes with cenobamate (CNB) in a large series of patients with highly drug‐resistant epilepsy within a Spanish Expanded Access Program (EAP). Method This was a multicenter, retrospective, observational study in 14 hospitals. Inclusion criteria were age ≥18 years, focal seizures, and EAP authorization. Data were sourced from patient clinical records. Primary effectiveness endpoints included reductions (100%, ≥90%, ≥75%, and ≥50%) or worsening in seizure frequency at 3‐, 6‐, and 12‐month visits and at the last visit. Safety endpoints included rates of adverse events (AEs) and AEs leading to discontinuation. Results The study included 170 patients. At baseline, median epilepsy duration was 26 years and median number of seizures/month was 11.3. The median number of prior antiseizure medications (ASMs) and concomitant ASMs were 12 and 3, respectively. Mean CNB dosages/day were 176 mg, 200 mg, and 250 mg at 3, 6, and 12 months. Retention rates were 98.2%, 94.5%, and 87% at 3, 6, and 12 months. At last available visit, the rate of seizure freedom was 13.3%; ≥90%, ≥75%, and ≥50% responder rates were 27.9%, 45.5%, and 63%, respectively. There was a significant reduction in the number of seizures per month (mean: 44.6%; median: 66.7%) between baseline and the last visit ( P < 0.001). Responses were maintained regardless of the number of prior or concomitant ASMs. The number of concomitant ASMs was reduced in 44.7% of patients. The cumulative percentage of patients with AEs and AEs leading to discontinuation were 68.2% and 3.5% at 3 months, 74.1% and 4.1% at 6 months, and 74.1% and 4.1% at 12 months. The most frequent AEs were somnolence and dizziness. Significance In this highly refractory population, CNB showed a high response regardless of prior and concomitant ASMs. AEs were frequent but mostly mild‐to‐moderate, and few led to discontinuation." @default.
• W4375846612 created "2023-05-10" @default.
• W4375846612 creator A5006709259 @default.
• W4375846612 creator A5011383975 @default.
• W4375846612 creator A5023230012 @default.
• W4375846612 creator A5026323662 @default.
• W4375846612 creator A5031062504 @default.
• W4375846612 creator A5041611958 @default.
• W4375846612 creator A5043114705 @default.
• W4375846612 creator A5045776943 @default.
• W4375846612 creator A5061038625 @default.
• W4375846612 creator A5065685036 @default.
• W4375846612 creator A5066520183 @default.
• W4375846612 creator A5072672839 @default.
• W4375846612 creator A5073341351 @default.
• W4375846612 creator A5074159489 @default.
• W4375846612 creator A5075747351 @default.
• W4375846612 creator A5082254672 @default.
• W4375846612 creator A5082413302 @default.
• W4375846612 creator A5087559167 @default.
• W4375846612 creator A5092335900 @default.
• W4375846612 creator A5092335901 @default.
• W4375846612 date "2023-05-21" @default.
• W4375846612 modified "2023-10-18" @default.
• W4375846612 title "Real‐world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program" @default.
• W4375846612 cites W1484035603 @default.
• W4375846612 cites W1570968506 @default.
• W4375846612 cites W1920696238 @default.
• W4375846612 cites W2107427879 @default.
• W4375846612 cites W2567656920 @default.
• W4375846612 cites W2601045941 @default.
• W4375846612 cites W2777270043 @default.
• W4375846612 cites W2988342087 @default.
• W4375846612 cites W3025465714 @default.
• W4375846612 cites W3025691036 @default.
• W4375846612 cites W3086758027 @default.
• W4375846612 cites W3130516526 @default.
• W4375846612 cites W3180396895 @default.
• W4375846612 cites W3190767033 @default.
• W4375846612 cites W3207548016 @default.
• W4375846612 cites W3207591866 @default.
• W4375846612 cites W3216724966 @default.
• W4375846612 cites W4205202155 @default.
• W4375846612 cites W4205689789 @default.
• W4375846612 cites W4210571854 @default.
• W4375846612 cites W4220780237 @default.
• W4375846612 cites W4225332941 @default.
• W4375846612 cites W4282963721 @default.
• W4375846612 cites W4285092783 @default.
• W4375846612 cites W4293194614 @default.
• W4375846612 cites W4294530663 @default.
• W4375846612 cites W4297994782 @default.
• W4375846612 cites W4300981629 @default.
• W4375846612 cites W4317567204 @default.
• W4375846612 cites W4317568104 @default.
• W4375846612 cites W4320856353 @default.
• W4375846612 cites W4322719179 @default.
• W4375846612 cites W4375846612 @default.
• W4375846612 doi "https://doi.org/10.1002/epi4.12757" @default.
• W4375846612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37149853" @default.
• W4375846612 hasPublicationYear "2023" @default.
• W4375846612 type Work @default.
• W4375846612 citedByCount "9" @default.
• W4375846612 countsByYear W43758466122023 @default.
• W4375846612 crossrefType "journal-article" @default.
• W4375846612 hasAuthorship W4375846612A5006709259 @default.
• W4375846612 hasAuthorship W4375846612A5011383975 @default.
• W4375846612 hasAuthorship W4375846612A5023230012 @default.
• W4375846612 hasAuthorship W4375846612A5026323662 @default.
• W4375846612 hasAuthorship W4375846612A5031062504 @default.
• W4375846612 hasAuthorship W4375846612A5041611958 @default.
• W4375846612 hasAuthorship W4375846612A5043114705 @default.
• W4375846612 hasAuthorship W4375846612A5045776943 @default.
• W4375846612 hasAuthorship W4375846612A5061038625 @default.
• W4375846612 hasAuthorship W4375846612A5065685036 @default.
• W4375846612 hasAuthorship W4375846612A5066520183 @default.
• W4375846612 hasAuthorship W4375846612A5072672839 @default.
• W4375846612 hasAuthorship W4375846612A5073341351 @default.
• W4375846612 hasAuthorship W4375846612A5074159489 @default.
• W4375846612 hasAuthorship W4375846612A5075747351 @default.
• W4375846612 hasAuthorship W4375846612A5082254672 @default.
• W4375846612 hasAuthorship W4375846612A5082413302 @default.
• W4375846612 hasAuthorship W4375846612A5087559167 @default.
• W4375846612 hasAuthorship W4375846612A5092335900 @default.
• W4375846612 hasAuthorship W4375846612A5092335901 @default.
• W4375846612 hasBestOaLocation W43758466121 @default.
• W4375846612 hasConcept C108759981 @default.
• W4375846612 hasConcept C118552586 @default.
• W4375846612 hasConcept C126322002 @default.
• W4375846612 hasConcept C162156334 @default.
• W4375846612 hasConcept C167135981 @default.
• W4375846612 hasConcept C187212893 @default.
• W4375846612 hasConcept C197934379 @default.
• W4375846612 hasConcept C23131810 @default.
• W4375846612 hasConcept C2775832928 @default.
• W4375846612 hasConcept C2778186239 @default.
• W4375846612 hasConcept C2778715236 @default.
• W4375846612 hasConcept C2779307984 @default.

• next